Myocardial Infarction - Pipeline Review, H2 2020

September 2020 | 385 pages | ID: MD027BAF1AAEN
Global Markets Direct

Abstracts

Myocardial Infarction - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2020, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.
Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 21, 9, 50, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 18 and 4 molecules, respectively.
Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Myocardial Infarction - Overview
Myocardial Infarction - Therapeutics Development
Myocardial Infarction - Therapeutics Assessment
Myocardial Infarction - Companies Involved in Therapeutics Development
Myocardial Infarction - Drug Profiles
Myocardial Infarction - Dormant Projects
Myocardial Infarction - Discontinued Products
Myocardial Infarction - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocardial Infarction, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H2 2020
Myocardial Infarction - Pipeline by Angion Biomedica Corp, H2 2020
Myocardial Infarction - Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2020
Myocardial Infarction - Pipeline by Aposcience AG, H2 2020
Myocardial Infarction - Pipeline by Applied Therapeutics Inc, H2 2020
Myocardial Infarction - Pipeline by Aprogen Inc, H2 2020
Myocardial Infarction - Pipeline by APT Therapeutics Inc, H2 2020
Myocardial Infarction - Pipeline by AptaTargets SL, H2 2020
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2020
Myocardial Infarction - Pipeline by Athera Biotechnologies AB, H2 2020
Myocardial Infarction - Pipeline by Axolo Pharma Inc, H2 2020
Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H2 2020
Myocardial Infarction - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Myocardial Infarction - Dormant Projects, H2 2020
Myocardial Infarction - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocardial Infarction, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Actinogen Medical Ltd
Angion Biomedica Corp
Ankasa Regenerative Therapeutics Inc
Aposcience AG
Applied Therapeutics Inc
Aprogen Inc
APT Therapeutics Inc
AptaTargets SL
AstraZeneca Plc
Athera Biotechnologies AB
Axolo Pharma Inc
Bharat Biotech Ltd
Boehringer Ingelheim International GmbH
Cadila Healthcare Ltd
CardioCreate Inc
Cardior Pharmaceuticals GmbH
CeleCor Therapeutics Inc
Celixir Ltd
CellProthera SAS
CFM Pharma Holding BV
Curacle Co Ltd
Cynata Therapeutics Ltd
DeckTherapeutics Inc
Diffusion Pharmaceuticals Inc
Domainex Ltd
Eight Plus One Pharmaceutical Co Ltd
EndoProtech Inc
Ever Supreme Bio Technology Co Ltd
Evotec SE
EyeGene Inc
Faraday Pharmaceuticals Inc
General Regeneratives Shanghai Ltd
Generium
GNT Pharma Co Ltd
Hemostemix Inc
Honya Medical Inc
HUYA Bioscience International LLC
Idorsia Pharmaceutical Ltd
iHeart Japan Corp
InCarda Therapeutics Inc
Innolife Co Ltd
Inotrem SA
IPS Heart Inc
Kine Sciences
Lee's Pharmaceutical Holdings Ltd
LTT Bio-Pharma Co Ltd
MandalMed Inc
Marizyme Inc
Merck & Co Inc
Mesoblast Ltd
MIFCOR Inc
MimeTech Srl
Mirae Cell Bio Co Ltd
Miragen Therapeutics Inc
New World Laboratories Inc
Novartis AG
NuvOx Pharma LLC
OMEICOS Therapeutics GmbH
OP2 Drugs SAS
Opsona Therapeutics Ltd
OtiTopic LLC
Oxstem Ltd
Pharmahungary Group
Primary Peptides Inc
Quark Pharmaceuticals Inc
Qurgen Inc
R Pharm
Reata Pharmaceuticals Inc
Recardio GmbH
RegeneRx Biopharmaceuticals Inc
ResoTher Pharma ApS
Rubicon Biotechnology Inc
Sentan Pharma Inc
Serca Pharmaceuticals AS
Serpin Pharma LLC
Silver Creek Pharmaceuticals Inc
Sorrento Therapeutics Inc
T&R Biofab Co Ltd
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Thrombolytic Science International LLC
Translational Sciences Inc
Vaxil Bio Therapeutics Ltd
XBiotech Inc
Xcelthera INC
Yichang Humanwell Pharmaceutical Co Ltd
Yuyu Pharma Inc
Zensun (Shanghai) Sci & Tech Co Ltd